Cytosorbents Cost of Goods Sold 2010-2024 | CTSO
Cytosorbents cost of goods sold from 2010 to 2024. Cost of goods sold can be defined as the difference between beginning and ending inventories for tangible products resulting in an expense that reflects production and sales costs.
| Cytosorbents Annual Cost of Goods Sold (Millions of US $) |
|
|---|---|
| 2024 | $10 |
| 2023 | $9 |
| 2022 | $14 |
| 2021 | $11 |
| 2020 | $11 |
| 2019 | $7 |
| 2018 | $7 |
| 2017 | $6 |
| 2016 | $4 |
| 2015 | $2 |
| 2014 | $2 |
| 2013 | $2 |
| 2012 | $0 |
| 2011 | $0 |
| 2010 | $0 |
| 2009 | $0 |
| Cytosorbents Quarterly Cost of Goods Sold (Millions of US $) |
|
|---|---|
| 2024-12-31 | $0 |
| 2024-09-30 | $4 |
| 2024-06-30 | $3 |
| 2024-03-31 | $3 |
| 2023-12-31 | $-1 |
| 2023-09-30 | $3 |
| 2023-06-30 | $3 |
| 2023-03-31 | $4 |
| 2022-12-31 | $4 |
| 2022-09-30 | $4 |
| 2022-06-30 | $4 |
| 2022-03-31 | $2 |
| 2021-12-31 | $3 |
| 2021-09-30 | $2 |
| 2021-06-30 | $3 |
| 2021-03-31 | $3 |
| 2020-12-31 | $3 |
| 2020-09-30 | $3 |
| 2020-06-30 | $3 |
| 2020-03-31 | $2 |
| 2019-12-31 | $2 |
| 2019-09-30 | $2 |
| 2019-06-30 | $2 |
| 2019-03-31 | $2 |
| 2018-12-31 | $2 |
| 2018-09-30 | $2 |
| 2018-06-30 | $2 |
| 2018-03-31 | $2 |
| 2017-12-31 | $1 |
| 2017-09-30 | $2 |
| 2017-06-30 | $1 |
| 2017-03-31 | $1 |
| 2016-12-31 | $1 |
| 2016-09-30 | $1 |
| 2016-06-30 | $1 |
| 2016-03-31 | $1 |
| 2015-12-31 | $1 |
| 2015-09-30 | $1 |
| 2015-06-30 | $0 |
| 2015-03-31 | $0 |
| 2014-12-31 | $0 |
| 2014-09-30 | $0 |
| 2014-06-30 | $1 |
| 2014-03-31 | $1 |
| 2013-12-31 | $1 |
| 2013-09-30 | $1 |
| 2013-06-30 | $0 |
| 2013-03-31 | $0 |
| 2012-12-31 | $0 |
| 2012-09-30 | $0 |
| 2012-06-30 | $0 |
| 2012-03-31 | $0 |
| 2011-12-31 | $0 |
| 2011-09-30 | |
| 2011-06-30 | |
| 2011-03-31 | |
| 2010-12-31 | |
| 2010-09-30 | |
| 2010-06-30 | |
| 2010-03-31 | |
| 2009-12-31 | |
| 2009-09-30 | |
| 2009-06-30 | |
| 2009-03-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $0.059B | $0.036B |
| CytoSorbents Corporation is a therapeutic medical device company. It develops adsorbent polymer technology for applications in the medical field, primarily to provide blood purification for the treatment of acute and chronic health complications associated with blood toxicity. The Company's product include CytoSorb, which filters cytokines and treat potentially fatal cytokine storm and BetaSorb, which remove beta2-microglobulin from the blood of patients suffering from chronic kidney failure. CytoSorbents Corporation is headquartered in Monmouth Junction, New Jersey. | |||